AI-based mammography tool earns FDA nod

A women’s health technology company has received the FDA’s blessing to market deep learning-based software designed to help breast radiologists spot hard-to-find nascent cancers in 3D mammograms.

Hologic announced the win this week, saying its Genius AI cancer-detection product will supply stronger sensitivity than its predecessor while sharply reducing false positives.

The new software “delivers key metrics at the time of image acquisition to help radiologists categorize and prioritize cases by complexity and expected read time in order to optimize workflow and expedite patient care,” Hologic says.

The company adds that the new product is the only AI-powered offering in its market category that doesn’t require a dedicated server.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.